Novartis Vaccines and Diagnostics, 53100 Siena, Italy.
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11169-74. doi: 10.1073/pnas.1107941108. Epub 2011 Jun 20.
Oil-in-water emulsions have been successfully used to increase the efficacy, immunogenicity, and cross-protection of human vaccines; however, their mechanism of action is still largely unknown. Nlrp3 inflammasome has been previously associated to the activity of alum, another adjuvant broadly used in human vaccines, and MyD88 adaptor protein is required for the adjuvanticity of most Toll-like receptor agonists. We compared the contribution of Nlrp3 and MyD88 to the adjuvanticity of alum, the oil-in-water emulsion MF59, and complete Freund's adjuvant in mice using a three-component vaccine against serogroup B Neisseria meningitidis (rMenB). Although the basal antibody responses to the nonadjuvanted rMenB vaccine were largely dependent on Nlrp3, the high-level antibody responses induced by alum, MF59, or complete Freund's adjuvant did not require Nlrp3. Surprisingly, we found that MF59 requires MyD88 to enhance bactericidal antibody responses to the rMenB vaccine. Because MF59 did not activate any of the Toll-like receptors in vitro, we propose that MF59 requires MyD88 for a Toll-like receptor-independent signaling pathway.
油包水乳剂已成功用于提高人类疫苗的疗效、免疫原性和交叉保护作用;然而,其作用机制在很大程度上仍然未知。Nlrp3 炎性体先前与另一种广泛用于人类疫苗的佐剂——明矾的活性有关,而 MyD88 衔接蛋白是大多数 Toll 样受体激动剂佐剂作用所必需的。我们使用针对 B 群脑膜炎奈瑟菌(rMenB)的三组分疫苗比较了 Nlrp3 和 MyD88 对明矾、油包水乳剂 MF59 和完全弗氏佐剂佐剂作用的贡献。尽管对未佐剂 rMenB 疫苗的基础抗体反应在很大程度上依赖于 Nlrp3,但明矾、MF59 或完全弗氏佐剂诱导的高水平抗体反应不需要 Nlrp3。令人惊讶的是,我们发现 MF59 增强对 rMenB 疫苗的杀菌抗体反应需要 MyD88。由于 MF59 体外不能激活任何 Toll 样受体,我们提出 MF59 需要 MyD88 来激活 Toll 样受体非依赖的信号通路。